Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall

Author:

Danieli Maria1ORCID,Barretta Francesco2,Radaelli Stefano1,Fiore Marco1ORCID,Sangalli Claudia3,Barisella Marta4,Palassini Elena5,Miceli Rosalba2,Frezza Anna Maria5ORCID,Callegaro Dario1ORCID,Collini Paola4,Casali Paolo Giovanni5,Stacchiotti Silvia5ORCID,Gronchi Alessandro1

Affiliation:

1. Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

2. Department of Clinical Epidemiology and Trial Organization Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

3. Department of Radiotherapy Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

4. Department of Advanced Diagnostics Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

5. Department of Cancer Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Abstract

AbstractBackgroundTo explore the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS).MethodsAll consecutive patients with primary localized MFS and UPS of the extremities and trunk wall surgically treated with curative intent at our center (2005‐2021) were included. Clinical data including residual visible tumor (VT%) on surgical specimen and Response Evaluation Criteria in Solid Tumor (RECIST) were retrieved. Kaplan–Meier curves for overall survival and disease‐free survival, and cumulative incidence of local relapse and distant metastasis were estimated in a competing risk framework according to RECIST and VT%, overall and by treatment group. Cox and Fine and Gray multivariable models were performed.ResultsOf 693 patients affected by primary MFS and UPS, 233 (66 MFS and 167 UPS) were treated by neoadjuvant chemotherapy (naChT), radiotherapy (naRT), or both (naChT‐RT). VT% was ≤5% in 13/46 (28.2%), 24/99 (24.2%), and 40/88 (45.4%) patients, respectively. There were 11/46 (29.7%), 22/99 (22.7%), and 23/88 (26.1%) RECIST partial responses and 18/46 (48.6%), 59/99 (60.8%), and 60/88 (68.2%) RECIST stable disease, respectively. In naChT, a trend for a better survival was observed when VT% ≤5% (p = .09), whereas RECIST partial responses and stable disease had the same outcome. VT% was not associated with outcome in naRT or naChT‐RT, whereas RECIST response was.ConclusionIn primary localized MFS and UPS treated with neoadjuvant therapies, VT% seems more relevant than size reduction after naChT, whereas the opposite is true when naRT is administered alone or concurrent to ChT.

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3